Table 2.

Linear regression comparisons between apoB-100 concentrations measured by IN and non-HDL-P or apoB-100 concentrations measured by LC-MS/MS, VAP, ES-DMA, and NMR.

x Axisy AxisSlope (95% CI)Intercept (95% CI)r2
MeasurandMethodMeasurandMethod
apoB-100INapoB-100LC-MS/MS 1A0.7487 (0.7061–0.7913)75.75 (−6.10 to 157.60)0.9818
apoB-100INapoB-100LC-MS/MS 1B1.1389 (0.9302–1.3476)−505.47 (−906.92 to −104.03)0.8381
apoB-100INapoB-100LC-MS/MS 2A0.9167 (0.8828–0.9506)110.65 (45.51–175.79)0.9922
apoB-100INapoB-100LC-MS/MS 2B1.0047 (0.9456–1.0638)38.29 (−75.30 to 151.89)0.9805
apoB-100INapoB-100VAP0.8317 (0.7599–0.9035)259.92 (121.89–397.96)0.9589
apoB-100INnon-HDL-PES-DMA-10.7893 (0.7156–0.8630)343.44 (201.69–485.19)0.9523
apoB-100INnon-HDL-PES-DMA-20.9795 (0.8381–1.1209)222.03 (−49.92 to 393.98)0.8930
apoB-100INnon-HDL-PNMR LP30.8047 (0.7417–0.8678)−133.08 (−254.41 to −11.75)0.9659
apoB-100INnon-HDL-PNMR LP41.0228 (0.9559–1.0896)−101.13 (−229.69 to −27.42)0.9760